C
Christian Junghanss
Researcher at University of Rostock
Publications - 175
Citations - 3011
Christian Junghanss is an academic researcher from University of Rostock. The author has contributed to research in topics: Transplantation & Medicine. The author has an hindex of 20, co-authored 144 publications receiving 2514 citations.
Papers
More filters
Journal ArticleDOI
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
Hagop M. Kantarjian,Neil P. Shah,Jorge E. Cortes,Michele Baccarani,Mohan B. Agarwal,Maria Soledad Undurraga,Jianxiang Wang,Juan Julio Kassack Ipiña,Dong-Wook Kim,Michinori Ogura,Carolina Pavlovsky,Christian Junghanss,Jorge Milone,Franck E. Nicolini,Tadeusz Robak,Jan Van Droogenbroeck,Edo Vellenga,M. Brigid Bradley-Garelik,Chao Zhu,Andreas Hochhaus +19 more
TL;DR: Primary data showed superior efficacy for dasatinib compared with imatinib after 12 months, including significantly higher rates of complete cytogenetic response (CCyR), confirmed CCyR (primary end point), and major molecular response (MMR).
Journal ArticleDOI
Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study.
Hannes Wandt,Kerstin Schaefer-Eckart,Knut Wendelin,Bettina Pilz,Martin Wilhelm,Markus Thalheimer,Ulrich Mahlknecht,Anthony D. Ho,Markus Schaich,Michael Kramer,Martin Kaufmann,Lothar Leimer,Rainer Schwerdtfeger,Roland Conradi,Gottfried Dölken,Anne Friederike Klenner,Mathias Hänel,Regina Herbst,Christian Junghanss,Gerhard Ehninger +19 more
TL;DR: The therapeutic strategy could become a new standard of care after autologous stem-cell transplantation; however, prophylactic platelet transfusion should remain the standard for patients with acute myeloid leukaemia.
Journal ArticleDOI
Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential.
Luca M. Neri,Alice Cani,Am Martelli,Carolina Simioni,Christian Junghanss,Giovanna Tabellini,Francesca Ricci,P. L. Tazzari,Pasqualepaolo Pagliaro,James A. McCubrey,Silvano Capitani +10 more
TL;DR: It is pointed out that mTORC1 inhibitors, either as a single agent or in combination with Akt inhibitors, could represent a potential therapeutic innovative strategy in B-pre ALL.
Journal ArticleDOI
Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study
Haifa Kathrin Al-Ali,Nadja Jaekel,Christian Junghanss,Georg Maschmeyer,Rainer Krahl,Michael Cross,Gisa Hoppe,Dietger Niederwieser +7 more
TL;DR: Azacitidine is active and well tolerated in elderly patients with newly diagnosed AML, and lower marrow blasts on day 15 of cycle 1, irrespective of pretreatment count, predicted subsequent response.
Journal ArticleDOI
An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia
Axel Glasmacher,Oliver A. Cornely,Andrew J. Ullmann,Ulrich Wedding,Heinrich Bodenstein,Hannes Wandt,Christian Boewer,Rita Pasold,Hans-Heinrich Wolf,Mathias Hänel,Gottfried Dölken,Christian Junghanss,Reinhard Andreesen,Hartmut Bertz +13 more
TL;DR: There were no differences in the efficacy and safety of itraconazole and fluconazole prophylaxis in neutropenic patients with haematological malignancies and no differences were detected between treatment groups in proven or suspected invasive fungal infections or other endpoints.